Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.

摘要: Angiogenesis, the formation of new blood vessels, is essential for both tumor growth and metastasis. Recent advances in our understanding molecular mechanisms underlying angiogenesis process its regulation have led to discovery a variety pharmaceutical agents with anti-angiogenic activity. The potential application these inhibitors currently under intense clinical pre-clinical investigation. Compelling evidence suggests that vascular endothelial factor (VEGF) receptors play critical roles tumor-associated angiogenesis, they represent good targets therapeutic intervention. This has been demonstrated animal models which disabling function VEGF was shown inhibit We produced panel antibodies directed against receptor 2, KDR/Flk-1. These potently block VEGF/KDR/Flk-1 interaction, VEGF-stimulated activation proliferation human cells. Further, significantly inhibited several models. Antagonists and/or may offer higher specificity towards tumors reduced side effects, be less likely elicit drug resistance compared conventional therapy. Anti-angiogenesis therapy represents novel strategy treatment cancer other disorders where pathological involved.